SK Plasma and Aimed Bio form partnership for co-먹튀없는 바카라사이트 and licensing of ADC anticancer drug

[by Lee, Young Sung] SK Plasma, a company specializing in blood-derived products, is actively working on the 먹튀없는 바카라사이트 of next-generation targeted anticancer drugs.

SK Plasma announced on June 9 that it has entered into a co-먹튀없는 바카라사이트 and licensing agreement for ADC-based anticancer drugs with Aimed Bio, a company specializing in the 먹튀없는 바카라사이트 of antibody-drug conjugates (ADCs).

This marks the first instance in which SK Plasma, traditionally focused on rare and incurable disease treatments, has ventured into the 먹튀없는 바카라사이트 of ADC-based anticancer drugs.

Under the agreement, the two companies will collaborate on the 먹튀없는 바카라사이트 of ADC-based anticancer treatment candidates targeting ROR1, a protein expressed in various cancer types. Aimed Bio will be responsible for basic research and candidate substance discovery, while SK Plasma will handle 먹튀없는 바카라사이트 activities during the clinical and commercialization stages. ROR1 is an antigen that is overexpressed in multiple solid tumors as well as hematologic malignancies.

먹튀없는 바카라사이트s are a next-generation targeted anticancer treatment that combines antibodies with potent cytotoxic agents to selectively eliminate cancer cells.

Unlike conventional chemotherapy, which can even harm healthy cells, 먹튀없는 바카라사이트 therapy has the advantage of selectively binding to specific antigens on the surface of cancer cells and delivering the cytotoxic agent directly to these cells to kill the tumor. This approach is considered an innovative treatment, as it minimizes damage to healthy tissues while providing potent anticancer effects.

According to the global market research firm GlobalData, the global 먹튀없는 바카라사이트 market is projected to expand significantly, growing from around USD 14 billion (approximately KRW 18.9 trillion) in 2023 to an estimated USD 112 billion by 2030.

Aimed Bio is a company that has proven its technological competitiveness in the 먹튀없는 바카라사이트 field through a range of research achievements and multiple global technology transfer agreements.

“As Aimed Bio is a research and development-focused company, collaboration with partners that have clinical and licensing capabilities is crucial for the commercialization of novel drug candidates,” expressed Her Nam-gu, CEO of Aimed Bio. “SK Plasma possesses a deep understanding of biopharmaceuticals, as well as valuable experience and know-how accumulated from conducting domestic and international clinical trials and business development efforts. This partnership will increase the prospects for subsequent clinical trials and global commercialization of ADC-based new drugs,” he added.

SK Plasma’s strategy is to gradually expand its biopharmaceutical portfolio, focusing on the treatment of rare and intractable diseases and including ADC-based anticancer drugs.

In 2021, SK Plasma made a strategic investment in Curocell, a company engaged in the development of CAR-T (Chimeric Antigen Receptor T-cell) immune cell-based anticancer treatment. Curocell recently completed Phase 2 clinical trials for its next-generation CAR-T treatment, ‘RIMQARTO (Anbal-cel),’ and has submitted an application for product approval in Korea. The treatment is currently undergoing evaluation for drug reimbursement.

“Co-development with a partner like Aimed Bio, which has demonstrated strong research expertise and technological potential, holds great strategic significance in expanding our biopharmaceutical portfolio to include ADCs,” stated Kim Seung-joo, CEO of SK Plasma. “We will actively pursue further collaborations with companies that possess innovative technologies aimed at improving treatment accessibility in the field of rare and intractable diseases.”

On the other hand, Aimed Bio is a spin-off from Samsung Medical Center, established in 2018 on the foundation of more than 30 years of research by Professor Nam Do-hyun, a globally recognized expert in brain tumors. The company boasts a big data-driven target discovery platform, an in-house antibody 먹튀없는 바카라사이트 platform, a preclinical evaluation platform utilizing PDC/PDX models, and a proprietary linker-payload platform. Earlier this year, Aimed Bio successfully transferred technology for an ADC novel drug candidate to Biohaven in the United States.